Articles by Christian Pinsonault - Pharmaceutical Representative
Saturday, Nov 21, 2009
Search

Articles by Christian Pinsonault

Christian Pinsonault

Managing Partner, Pinsonault Associates

Christian Pinsonault is a managing partner at Flanders, NJ-based Pinsonault Associates LLC, a managed care training and information company for the pharmaceutical and biotechnology industries. The company recently launched a new CD-ROM program for representatives entitled Medicare: Changing the Face of Healthcare. He can be reached at (800) 372-9009 or by e-mail at christian@pinsonault.com.

Articles
Elected coverage
February 1, 2008

It's no surprise that voters have identified healthcare as a leading domestic issue for presidential candidates to address in the current campaign. With soaring costs, rising premiums, reduced (or even discontinued) employer coverage and 47 million uninsured Americans, voters have every right to be concerned.

Owning your territory
September 1, 2007

In a Sense, your Territory is a sole proprietorship. You "own" it. You manage it, and at the end of the year, the health of its bottom line is dependent upon your business savvy.

The loneliest customer
December 1, 2006

While physicians in your territory will always be your primary sales targets, never lose sight of the fact that the retail pharmacist deserves a regular slot on your call schedule.

Payday
March 1, 2006

When reps understand how physicians are paid, they gain insights into how financial factors influence prescribing behavior. Then they can fine-tune their messages to help address physician needs while ensuring appropriate utilization of their products.

Beyond the doughnut hole
December 1, 2005

What you need to know about the new Medicare Part D benefit plans.

ADVERTISEMENT

Survey
The more people talk about healthcare reform the less consensus there is, what do you think of current efforts to reform the system?
Healthcare reform is
Good for pharma
Bad for pharma
Doomed to failure
An idea whose time has come
Good for pharma
18%
Bad for pharma
37%
Doomed to failure
24%
An idea whose time has come
21%
GOOGLE ADVERTISEMENTS
Click here